Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.
Type:
Grant
Filed:
August 31, 2017
Date of Patent:
August 15, 2023
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Assistance Publique—Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles—St. Quentin en Yvelines
Inventors:
Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
August 15, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), NANTES UNIVERSITÈ, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
August 15, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.
Type:
Grant
Filed:
August 22, 2019
Date of Patent:
August 15, 2023
Assignees:
INSTITUT PASTEUR, FONDATION IMAGINE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS CITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Gerard Eberl, David Bikard, Pamela Schnupf, Nadine Cerf Bensussan, Valerie Gaboriau-Routhiau, Philippe Sansonetti
Abstract: An in vitro method of classifying a subject suspected to suffer from an acute event including the steps of: determining neopterin concentration in a biological sample obtained from the subject, comparing the concentration with a predetermined reference neopterin concentration, and assigning the subject to a risk group based on the comparison of the neopterin concentration with the predetermined reference neopterin concentration.
Type:
Application
Filed:
July 12, 2021
Publication date:
August 10, 2023
Applicants:
SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
August 8, 2023
Assignees:
SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
Type:
Grant
Filed:
June 22, 2020
Date of Patent:
August 8, 2023
Assignees:
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, ECOLE D'INGENIEURS DE PURPAN
Inventors:
Philippe Langella, Sylvie Miquel, Rebeca Martin Rosique, Luis Bermudez Humaran, Muriel Thomas, Harry Sokol, Frédéric Carvalho, Vassilia Theodorou
Abstract: The invention relates to a method of preparation of a recombinant hybrid adeno-associated virus (AAV) capsid protein with improved tropism and to the recombinant hybrid AAV capsid protein obtainable by the method. The invention relates also to the derived expression vector, modified cell, and hybrid capsid AAV vector particle packaging a gene of interest, and its use in tissue-targeted gene therapy for treating various diseases.
Type:
Application
Filed:
July 5, 2021
Publication date:
August 3, 2023
Applicants:
Genethon, Institut National de la Santé et de la Recherche Médicale, Universite d'Evry Val d'Essonne
Abstract: A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
August 1, 2023
Assignees:
Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), Sorbonne Universite
Inventors:
Marie-Charlotte Horny, Jean-Michel Siaugue, Vincent Dupuis, Mathieu Lazerges, Jean Gamby
Abstract: The disclosure relates to the use of clofoctol in the prevention or treatment of a disease caused by a coronavirus, in particular Covid-19.
Type:
Application
Filed:
June 8, 2021
Publication date:
July 27, 2023
Applicants:
Apteeus, Universite De Lille, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale, Centre Hospitalier Universitaire De Lille
Abstract: An ultrasound cardiac stimulation system includes: a system for measuring the heart electrical activity; a system for generating a beam of focussed ultrasound signals focussed on a targeted zone, the signals being calibrated to generate electrical stimulation in a zone of the heart, the beam generation being synchronised with a first selected time of the electrocardiogram, the generation of the beam corresponding to a pulse with a duration of less than 80 ms; a system for locating the targeted zone coupled with a system for positioning the system for generating the focussed beam to control the beam of focussed ultrasound signals in the targeted zone, the location system being synchronised with the system for generating the beam of focussed signals; a single monitoring system following in real time a temperature and tissue deformation in the targeted zone, the monitoring system taking measurements in synchronisation with the rhythm of the electrocardiogram.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
July 25, 2023
Assignees:
UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX
Inventors:
Fabrice Marquet, Pierre Bour, Bruno Quesson, Fanny Vaillant, Remi Dubois
Abstract: A method for printing uses at least one bio-ink. The method also uses at least one laser print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of a receiving substrate. The printing method uses at least one nozzle print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of the same receiving substrate as the laser print head.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
July 25, 2023
Assignees:
Universite de Bordeaux, Institut National de la Sante et de la Recherche Medicale-lnserm
Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
Type:
Grant
Filed:
March 29, 2021
Date of Patent:
July 25, 2023
Assignees:
AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
July 18, 2023
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.
Type:
Grant
Filed:
May 26, 2021
Date of Patent:
July 18, 2023
Assignee:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.
Type:
Application
Filed:
November 6, 2020
Publication date:
July 13, 2023
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
July 11, 2023
Assignees:
OGD2 PHARMA, NANTES UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE CANCEROLOGIE DE L'OUEST
Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
July 11, 2023
Assignees:
Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur